Search

Displaying results 1991 - 2000 of 3180 in total
  1. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with rituximab (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse o...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  2. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    Brepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. It inhibits TYK2- and JAK1-mediated cytokine signaling, blocking phosphorylation of signal transducers and activat...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  3. Drug

    Avutometinib

    go.drugbank.com/drugs/DB15254
    ApprovedInvestigational

    Avutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, diff...

    Synonyms: N-(3-fluoro-4-((4-methyl-2-oxo-7-((pyrimidin-2-yl)oxy)-2H-1-benzopyran-3-yl)methyl)pyridin-2-yl)-N'-methylsulfuric diamide, Sulfamide, N-(3-fluoro-4-((4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-1-benzopyran-3-yl)methyl)-2-pyridinyl)-N'-methyl-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Sotorasib

    go.drugbank.com/drugs/DB15569
    ApprovedInvestigational

    Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  5. Drug

    Homochlorcyclizine

    go.drugbank.com/drugs/DB15979
    Investigational

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  6. Drug

    Ubenimex

    go.drugbank.com/drugs/DB03424
    Investigational

    It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.

  7. Drug

    Equilenin

    go.drugbank.com/drugs/DB03515
    Experimental

    Equilenin is an estrogenic steroid produced by horses. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the urine of pregnant mares.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Tiratricol

    go.drugbank.com/drugs/DB03604
    ApprovedInvestigational

    Tiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3). It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transport...

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  9. Drug

    Ribostamycin

    go.drugbank.com/drugs/DB03615
    ApprovedWithdrawn

    Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.

  10. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates